Alemtuzumab treatment of multiple sclerosis

Seminars in Neurology

Volumn 33, Issue 1, 2013, Pages 66-73

  Coles, Alasdair J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

alemtuzumab; antibody; multiple sclerosis

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BETA1A INTERFERON; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; AUTOIMMUNITY; BURKITT LYMPHOMA; CD4+ CD25+ T LYMPHOCYTE; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; DISEASE DURATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; FLU LIKE SYNDROME; GINGIVITIS; GRANULOMA; HUMAN; INNATE IMMUNITY; LEUKOENCEPHALOPATHY; LISTERIOSIS; MOLECULAR WEIGHT; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RELAPSE; RESPIRATORY TRACT INFECTION; THROMBOCYTOPENIA; THYROID CARCINOMA; URINARY TRACT INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 84878344070     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0033-1343797     Document Type: Article

References (45)

1. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature: 1975; 256 5517 495 497
2. Waldmann H., Hale G. CAMPATH: from concept to clinic. Philos Trans R Soc Lond B Biol Sci: 2005; 360 1461 1707 1711 (Pubitemid 43997819)
3. Lockwood C. M., Hale G., Waldman H., Jayne D. R. Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford): 2003; 42 12 1539 1544 (Pubitemid 37508929)
4. Dick A. D., Meyer P., James T., et al. Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol: 2000; 84 1 107 109 (Pubitemid 30251643)
5. Isaacs J. D., Hale G., Waldmann H., et al. Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H. Br J Ophthalmol: 1995; 79 11 1054 1055
6. Isaacs J. D., Hazleman B. L., Chakravarty K., Grant J. W., Hale G., Waldmann H. Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H. J Rheumatol: 1996; 23 6 1103 1106
7. Isaacs J. D., Manna V. K., Rapson N., et al. CAMPATH-1H in rheumatoid arthritis-an intravenous dose-ranging study. Br J Rheumatol: 1996; 35 3 231 240
8. Newman D. K., Isaacs J. D., Watson P. G., Meyer P. A., Hale G., Waldmann H. Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H. Eye (Lond): 1995; 9 Pt 5 564 569
9. Cheetham G. M., Hale G., Waldmann H., Bloomer A. C. Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart. J Mol Biol: 1998; 284 1 85 99 (Pubitemid 28523999)
10. Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy: 2001; 3 3 137 143 (Pubitemid 33039652)
11. Xia M. Q., Hale G., Lifely M. R., et al. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J: 1993; 293 Pt 3 633 640 (Pubitemid 23244542)
12. Xia M. Q., Tone M., Packman L., Hale G., Waldmann H. Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol: 1991; 21 7 1677 1684
13. Kirchhoff C., Krull N., Pera I., Ivell R. A major mRNA of the human epididymal principal cells, HE5, encodes the leucocyte differentiation CDw52 antigen peptide backbone. Mol Reprod Dev: 1993; 34 1 8 15 (Pubitemid 23014497)
14. Wing M. G., Moreau T., Greenwood J., et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest: 1996; 98 12 2819 2826 (Pubitemid 26427411)
15. Moreau T., Coles A., Wing M., et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain: 1996; 119 Pt 1 225 237 (Pubitemid 26077567)
16. Xia M. Q., Hale G., Waldmann H. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol Immunol: 1993; 30 12 1089 1096
17. Hu Y., Turner M. J., Shields J., et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology: 2009; 128 2 260 270
18. Waldmann H., Cobbold S. How do monoclonal antibodies induce tolerance? A role for infectious tolerance? Annu Rev Immunol: 1998; 16 619 644 (Pubitemid 28183379)
19. Hill-Cawthorne G. A., Button T., Tuohy O., et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry: 2012; 83 3 298 304
20. Cox A. L., Thompson S. AJ, Jones J. L., et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol: 2005; 35 11 3332 3342 (Pubitemid 41672537)
21. Thompson S. A., Jones J. L., Cox A. L., Compston D. A., Coles A. J. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol: 2010; 30 1 99 105
22. Coles A. J., Fox E., Vladic A., et al. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology: 2012; 78 14 1069 1078
23. Le Page E., Leray E., Taurin G., et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5. year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry: 2008; 79 1 52 56
24. Rebello P., Cwynarski K., Varughese M., Eades A., Apperley J. F., Hale G. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy: 2001; 3 4 261 267 (Pubitemid 34784622)
25. Rebello P., Hale G. Pharmacokinetics of CAMPATH-1H: assay development and validation. J Immunol Methods: 2002; 260 1-2 285 302 (Pubitemid 34132893)
26. Somerfield J., Hill-Cawthorne G. A., Lin A., et al. A novel strategy to reduce the immunogenicity of biological therapies. J Immunol: 2010; 185 1 763 768
27. Kurtzke J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology: 1983; 33 11 1444 1452 (Pubitemid 14237132)
28. Coles A. J., Cox A., Le Page E., et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol: 2006; 253 1 98 108 (Pubitemid 43157395)
29. Cohen J. A., Coles A. J., Arnold D. L., et al. for the CARE-MS I investigators Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomized controlled phase 3 trial. Lancet: 2012; 380 9856 1819 28
30. Coles A. J., Twyman C. L., Arnold D. L., et al. for the CARE-MS II investigators Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomized controlled phase 3 trial. Lancet: 2012; 380 9856 1829 39
31. Rudick R. A., Lee J. C., Simon J., Ransohoff R. M., Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol: 2004; 56 4 548 555 (Pubitemid 39319345)
32. Prosperini L., Gallo V., Petsas N., Borriello G., Pozzilli C. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol: 2009; 16 11 1202 1209
33. Rudick R. A., Polman C. H. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol: 2009; 8 6 545 559
34. Ebers G. C., Traboulsee A., Li D., et al. Investigators of the 16-year Long-Term Follow-Up Study Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry: 2010; 81 8 907 912
35. Shirani A., Zhao Y., Karim M. E., et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA: 2012; 308 3 247 256
36. Coles A. J., Fox E., Vladic A., et al. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol: 2011; 10 4 338 348
37. Kraimps J. L., Bouin-Pineau M. H., Mathonnet M., et al. Multicentre study of thyroid nodules in patients with Graves' disease. Br J Surg: 2000; 87 8 1111 1113 (Pubitemid 30496865)
38. Kim W. B., Han S-M, Kim T. Y., et al. Ultrasonographic screening for detection of thyroid cancer in patients with Graves' disease. Clin Endocrinol (Oxf): 2004; 60 6 719 725 (Pubitemid 38788080)
39. Berker D., Isik S., Ozuguz U., et al. Prevalence of incidental thyroid cancer and its ultrasonographic features in subcentimeter thyroid nodules of patients with hyperthyroidism. Endocrine: 2011; 39 1 13 20
40. Hsiao L. T., Liu J. H., Yen C. C., et al. Relapse of Graves' disease after successful allogeneic bone marrow transplantation. Bone Marrow Transplant: 2001; 28 12 1151 1153
41. Gilquin J., Viard J. P., Jubault V., Sert C., Kazatchkine M. D. Delayed occurrence of Graves' disease after immune restoration with HAART. Highly active antiretroviral therapy. Lancet: 1998; 352 9144 1907 1908 (Pubitemid 28561258)
42. Broadley S. A., Deans J., Sawcer S. J., Clayton D., Compston D. AS. Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey. Brain: 2000; 123 Pt 6 1102 1111 (Pubitemid 30312103)
43. Heinzlef O., Alamowitch S., Sazdovitch V., et al. Autoimmune diseases in families of French patients with multiple sclerosis. Acta Neurol Scand: 2000; 101 1 36 40 (Pubitemid 30022044)
44. Clatworthy M. R., Wallin E. F., Jayne D. R. Anti-glomerular basement membrane disease after alemtuzumab. N Engl J Med: 2008; 359 7 768 769
45. Jones J. L., Phuah C. L., Cox A. L., et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest: 2009; 119 7 2052 2061